Cancer Prevention with Molecular Target Therapies

• Muut tekijät: Paleari, Laura (Toimittaja)
• Aineistotyyppi: Elektroninen Kirjan osa
• Kieli: englanti
• Julkaistu: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
• Aiheet: Medicine; Oncology; melanoma; β3-tubulin; microtubules; microvesicles; endometrial cancer; steroid receptors; aromatase inhibitors; progression free survival; overall survival; ALK; EGFR; non-small-cell lung cancer (NSCLC); immune checkpoint inhibitor (ICI); adenocarcinoma; GANT61; non-canonical Hedgehog-GLI signaling; hepatocellular carcinoma; tyrosine kinase inhibitor; multidrug resistance; cancer; ABC transporter; SLC transporter; lysosomal sequestration; cancer cell migration; prognosis; biomarker; extracellular vesicles; lipid metabolism; human thymidylate synthase peptidic-inhibitors; pH-sensitive PEGylated liposomes; ovarian cancer; drug-resistance; raltitrexed; 5-fluorouracil; bladder cancer; muscle invasive; non-muscle invasive; molecular subtypes; evolution; targeted therapy; classification; gut microbiota; NAFLD; HCC; dysbiosis; metabolites; NSCLC; early stage; osimertinib; DMTF1; ARF; INK4a; p53; Cyclin D1; YY1; STAT3; tumor promoter; tumor suppressor
• Linkit: DOAB: download the publication; DOAB: description of the publication

Personalized medicine plays an important role in cancer prevention. To date, it is clear that many cancers are molecularly distinct subtypes, and different therapeutic approaches would be required for each. Indeed, the identification of cancer susceptibility genes permits identifying patients "...